Re: Coronary Artery Calcium Score
in response to
by
posted on
Feb 17, 2019 09:16PM
Some discussions of apabetalone and coronary artery calcium scoring appeared this weekend on the other boards, so I am re-posting this post from December on this same issue to add to the discussion.
BearDownAZ
--------------------------
From the discussion section of the latest Resverlogix publication on vascular calcification:
"Future studies will determine if apabetalone affects biomarkers or coronary artery calcium score in patients at risk of VC and its complications."
I've been noticing a lot of talk about the utility of widespread screening/testing for coronary artery calcium score (CACS) to identify patients most at risk for cardiovascular disease. There is also growing evidence that elevated serum alkaline phosphatase levels are positively associated with an elevated CACS. It will be great if BETonMACE confirms that apabetalone reduces alkaline phosphatase levels (pre-specified secondary endpoint) as previously shown in post-hoc of SUSTAIN/ASSURE. If so, the next question is whether apabetalone improves the CACS. Perphaps in addition to BETonRENAL, they can do a BETonCACS trial in patients with high baseline CACS? I wonder if the docs obtained a baseline CACS in the BETonMACE patients so that they can measure change in CACS between baseline and end of study in BETonMACE?
Coronary Artery Calcium Scoring: Who Should Be Tested, and What Comes Next?
Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring